Global collaboration action for the development of vaccines for reducing the disease burden of Tuberculosis in sub-Saharan Africa

Last updated: 16.7.2025
Grant

This funding program, under the Horizon Europe Framework, aims to reduce the burden of Tuberculosis in sub-Saharan Africa through global collaborative actions focused on vaccine development. It prioritizes accelerating the clinical development of new and licensed TB vaccine candidates and enhancing their availability and affordability in low-resource settings.

Who is Funded

This section outlines the types of organizations and geographical areas eligible for funding, focusing on collaborative efforts to combat Tuberculosis in sub-Saharan Africa. The program seeks to involve a broad range of entities from EU, associated, and African countries to achieve its global health objectives.

What is Funded

This section details the types of projects and research activities that are eligible for funding, specifically emphasizing clinical development of Tuberculosis vaccines and related data generation. The program supports impactful research that contributes to public health outcomes.

Type and Scope of Funding

This section outlines the financial mechanisms and scale of support provided, highlighting that the program primarily offers grants for collaborative research actions in vaccine development. Projects are expected to leverage significant co-contributions from partners.

Conditions and Requirements

This section details the essential criteria and regulations that applicants and beneficiaries must adhere to, ranging from consortium composition to the exploitation and accessibility of research outcomes. Key emphasis is placed on collaborative structures and ensuring public access to developed health technologies.

Application Procedure

This section outlines the structured, two-stage application process, detailing submission requirements, evaluation criteria, and how proposals are assessed based on their scientific merit, expected impact, and implementation quality.

This section identifies the core legal and regulatory framework that underpins the funding program, ensuring its mandate and operational guidelines are clearly defined within the broader European Union legal landscape.

Similar Programs

#Tuberculosis vaccines#sub-Saharan Africa#global health#clinical trials#EU funding#Infectious diseases#vaccine development#public health#Horizon Europe#EDCTP3#research and innovation#health technologies#access to medicines#poverty-related diseases#immunology#clinical studies#medical interventions

Funding Overview

Funding Status

Funding Status:

Closed

Maximum Amount

Maximum Amount:

15,300,000 €

Allocated Budget

Allocated Budget:

45,900,000 €

Award Channel

Award Channel:

Framework Programme Call

Region

Region:

European Union Member States, Overseas Countries and Territories (OCTs) linked to EU Member States, Horizon Europe Associated Countries (including Albania, Armenia, Bosnia and Herzegovina, Canada, Faroe Islands, Georgia, Iceland, Israel, Kosovo, Moldova, Montenegro, New Zealand, North Macedonia, Norway, Serbia, Tunisia, Turkey, Ukraine, United Kingdom), countries with association negotiations in process (Morocco, South Korea, Switzerland), and constituent states of the EDCTP Association (Benin, Burkina Faso, Cameroon, Côte d’Ivoire, Democratic Republic of the Congo, Ethiopia, Eswatini, Gabon, The Gambia, Ghana, Guinea-Bissau, Guinea-Conakry, Kenya, Liberia, Malawi, Mali, Mozambique, Niger, Nigeria, Republic of the Congo, Rwanda, Senegal, Sierra Leone, Somalia, South Africa, Tanzania, Uganda, Zambia, Zimbabwe). The primary focus for project activities is sub-Saharan Africa.

Sectors

Sectors:

Healthcare, Research and Development, Pharmaceutical Industry, Other

Beneficiaries

Beneficiaries:

Adolescents, adults, pregnant and lactating women, new-borns, children, other vulnerable and neglected populations, and people with co-infections and co-morbidities at risk in sub-Saharan Africa.

Application Type

Application Type:

Consortium Required

Funding Stages

Funding Stages:

Applied Research, Experimental Development, Prototyping, Pilot Testing, Product Development, Commercialization

Funding Provider

Program Level:

Multi-Country

Funding Body:

Global Health EDCTP3 Joint Undertaking (JU)

Managed By:

Global Health EDCTP3 JU Programme Office

Additional Partners:

Contributing partners (providing financial and/or in-kind contributions), Team Europe Initiative on Manufacturing and Access to Vaccines, medicines and health products (TEI-MAV+), or similar African initiatives.

0 x 0
XS